Covid vaccine equity remains out of reach, as wealthy nations drag their feet on donations, and vaccine stocks pass their use-by dates. By Lucien Hordijk and Priti Patnaik | 23 May 2022 Though Brussels was largely successful in buying billions of covid-19 vaccine doses for an entire continent, circumventing nationalist policies and bidding wars between member states, it …
How Europe’s vaccine donations went tragically wrong Read More »
The patent on the cancer drug Revlimid (lenalidomide) recently expired. Whereas a few weeks ago a pack still cost over 4,500 euros, after generic competition this is now only about 20 euros. This means that Dutch hospitals will save over 130 million euros. Many of the main criticisms of the industry come together in this …
Now that the patent has expired, this cancer drug is suddenly 99% cheaper Read More »
Using a set of legal tricks, the pharmaceutical industry was able to turn an animal gallic acid into a medicine that costs tons of money per year. Responsible pharmacist of the Amsterdam Medical Center Marleen Kemper and professor in metabolic diseases Carla Hollak decided in 2018 to start preparing the drug chenodeoxycholic acid (CDCA) for …
Amsterdam Medical Center creates ‘hijacked’ medicine Read More »
Pharmaceutical firm Novartis charges €2 million for a single intravenous infusion — but the National Health Care Institute in the Netherlands declared in April that it cannot be sold for more than €155,000. The Investigative Desk dug into how medicines can be made so expensive, and how scientists burnish their careers by earning billions for …
Leaked documents show that the European Commission put pressure on the European Medicines Agency to approve the first Covid-19 vaccines simultaneously with the American FDA. This happened when the regulator still had serious questions about the purity of the vaccine. According to the European Medicines Agency, in a press release issued on 15 January, confidential …
Brussels pressured drug regulator to approve Pfizer vaccine Read More »
The drug’s manufacturer was aware of the negative results of the Solidarity trial before the European Commission struck a procurement deal with it, finds an investigation. Read the full article here. On 7 October the European Commission struck a so called joint procurement framework deal with the drug manufacturer Gilead, after reports the day before …
A Dutch advocacy group claims that women receive worse care than men, because pharmaceutical companies do not sufficiently test their medicines on women. A shocking message, for which there is no evidence. In fact, The Investigative Desk found that in reality, more than 60 percent of patients in last year’s phase 3 trials were female. …
Most of the demand for (refresher) training courses for doctors in the Netherlands is fulfilled by industry- sponsored programmes. Even after decades of controversy over drug companies influencing prescribing behaviour, doctors are not willing to pay for these courses themselves, according to a report of The Investigative Desk, published in the Dutch Journal of Medicine. …
Two decades of EU market protection of ‘orphan’ (rare disease) medicines have greatly benefitted the industry. According to research by The Investigative Desk, published in the British Medical Journal (BMJ) and the Dutch Journal of Medicine (NTvG), many of these ‘orphan medicines’ make billions of euros. Twenty years ago, the European Commission introduced a legislation …
New innovative medicines should be made available to European citizens more quickly. That is why the European Medicines Agency updates the process for market authorisation. Anthony Humphreys sighs when asked what the new strategy means for doctors. ‘What can I possibly say?’ The former pharmacist from Ireland is responsible for EMA’s ‘Regulatory Science to 2025’ …
The Investigative Desk is an independent platform for investigative journalism, focusing on large international industrial sectors such as tobacco, food and chemicals, finance, energy, pharmaceuticals and health care, defence and security.
Read more